Madrigal Pharmaceuticals, Inc. (MDGL)
NMS · Healthcare · Biotechnology
$480.77
+1.37%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$11.08B
Shares Outstanding
23.1M
P/S (TTM)
9.8x
Exchange
NMS
Currency
USD
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 212.8M | 287.3M | 321.1M | 311.3M |
| Gross Profit | 203.7M | 269.1M | 296.6M | 284.5M |
| Operating Income | -47.2M | -114.0M | -59.6M | -92.7M |
| Net Income | -42.3M | -114.2M | -58.6M | -94.4M |
| Diluted EPS | $-1.90 | $-5.08 | $-2.57 | $-3.25 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 180.1M | 958.4M |
| Gross Profit | 0.00 | 0.00 | 173.9M | 902.3M |
| Operating Income | -293.6M | -380.5M | -497.9M | -300.1M |
| Net Income | -295.4M | -373.6M | -465.9M | -288.3M |
| Diluted EPS | $-17.23 | $-19.99 | $-21.90 | $-12.85 |